Inhibitor of 5α-Reductase Dutasteride in the Treatment of Benign Prostatic Hyperplasia: Systematic Review and Meta-Analysis

    May 2021
    Maksym Romaniuk, P. Aksonov
    TLDR Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
    The systematic review and meta-analysis evaluated the efficacy and safety of dutasteride, a 5-alpha-reductase inhibitor, in treating benign prostatic hyperplasia (BPH). The analysis included four studies with 1,879 patients and found that dutasteride significantly reduced the need for prostate surgery and episodes of acute urinary retention compared to finasteride, while maintaining a similar safety profile. No statistically significant differences in safety were observed between dutasteride and finasteride, highlighting dutasteride's superior clinical efficacy in managing BPH symptoms.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    6 / 1000+ results